Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Biotronik

Evaluate

Thumbnail
August 11, 2022

Reva revives

Thumbnail
January 17, 2020

Bioresorbable scaffolds flounder as Reva heads to bankruptcy

With Reva, Amaranth and Abbott out of the game, the pool of dissolving scaffold makers is shrinking.

Article image
Vantage logo
October 24, 2019

Diagnostics specialists win the US device approval race

The speediest device developer is Roche, but a look at companies’ strategies shows the perils of relying on bought-in tech.

Article image
Vantage logo
July 17, 2019

De novo device clearances fall out of fashion

The overall rate of device approvals in 2019 is holding steady on last year – but the types of approvals are different.

Article image
Vantage logo
June 17, 2019

FDA adcom to pronounce on paclitaxel-coated devices

The recent disappointing sales of drug-coated devices for peripheral arterial disease look likely to become the norm.

Article image
Vantage logo
May 21, 2018

Boston Scientific’s plan to keep the rhythm going

An acquisitive company has a plan for the future.

Article image
Vantage logo
May 11, 2018

Ablation groups scramble to cope with Cabana

The Cabana trial has finally reported, but the data are inconclusive.

Vantage logo
October 26, 2017

Interview – Amaranth struts towards the market

Vantage logo
August 27, 2017

ESC 2017 – Biotronik builds an impressive Castle

Vantage logo
August 04, 2017

Snippet roundup: Two approvals, two setbacks and a price war

Vantage logo
April 07, 2017

Snippet roundup: Merck gets Tecos knockback, Gottlieb moves towards FDA hotseat

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up